Lysosomal enzymes in cerebral atrophy

Area of Science:

• Biochemistry
• Neurology
• Medical Diagnostics

Background:

• Cerebral atrophy is associated with neurodegenerative diseases like pre-senile dementia and cerebrovascular disease.
• Enzyme activity in cerebrospinal fluid (CSF) and serum can serve as biomarkers for neurological disorders.
• Understanding specific enzyme alterations may aid in diagnosing and understanding the pathophysiology of cerebral atrophy.

Purpose of the Study:

• To investigate the activity levels of acid phosphatase, arylsulphatase, and beta-galactosidase in the CSF and serum of patients with cerebral atrophy.
• To compare these enzyme activities between patients and healthy controls.
• To determine the potential of these enzymes as biomarkers for cerebral atrophy.

Main Methods:

• Enzyme activity assays were performed on cerebrospinal fluid (CSF) and serum samples.
• Seven patients diagnosed with cerebral atrophy (due to pre-senile dementia and/or cerebrovascular disease) were included.
• Six healthy individuals served as the control group.

Main Results:

• Acid phosphatase activity was significantly higher (p < 0.05) in the CSF of patients compared to controls.
• Arylsulphatase and beta-galactosidase activities in CSF did not differ between patients and controls.
• Serum beta-galactosidase activity was significantly lower (p < 0.02) in patients with cerebral atrophy, while serum acid phosphatase and arylsulphatase showed no significant differences.

Conclusions:

• Elevated CSF acid phosphatase and reduced serum beta-galactosidase may be indicative of cerebral atrophy.
• These specific enzyme alterations could serve as potential diagnostic markers for conditions involving cerebral atrophy.
• Further research is warranted to elucidate the precise role of these enzymes in the pathogenesis of cerebral atrophy.